SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Array Biopharma, Inc
An SI Board Since March 2005
Posts SubjectMarks Bans Symbol
321 29 0 ARRY
Emcee:  keokalani'nui Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
221I would have had a very decent day today except I have too much ARRY. ACAD was etom pope-1/16/2013
220:-)scaram(o)uche-1/11/2013
219The fact that FDA has agreed to hematologic improvement as primary endpoint for mcbio-1/10/2013
218Good presentation. Clear route forward for 614, in event project looks go. Firstscaram(o)uche-1/8/2013
217Item 1.01 Entry into a Material Definitive Agreement. On November 29, 2012, Arscaram(o)uche-12/4/2012
216Yeah, and I believe Novartis. :-) Seriously, they've had plenty of time tscaram(o)uche-12/3/2012
215According to ARRY, NVS thinks their BRAF inhibitor will be the best. Hard to samcbio-12/3/2012
214I guess this is it.... operable primaries, and "adjuvant" in the surgiscaram(o)uche-12/3/2012
213GSK slide from their (ongoing) pipeline review.... expect (1) b-raf inhibitor toscaram(o)uche-12/3/2012
212Well, 520+carfilzomib ASH data is out. See: myelomabeacon.com . For six patiemcbio-11/19/2012
211Thanks for the additional color and caveats. I'm certainly not predicting smcbio-11/19/2012
210I just don't understand where the passion comes from, for a scientist, to descaram(o)uche211/19/2012
209I'm not sure I understand your skepticism on 520. Mind you, I had pretty mumcbio-11/17/2012
208Thanks! >> ARRY expects that there will be combo data for the 8, 9, or 1scaram(o)uche-11/16/2012
207ARRY @ Jefferies today: siliconinvestor.com .mcbio-11/15/2012
206I think any time a small-cap biotech has less than a year of cash remaining, as mcbio-11/9/2012
205Thanks again! True for all three pi3k-targeted Novartis molecules combo'd scaram(o)uche-11/9/2012
204As you suggested over on iHub, dilution is a fact of life in biotech investing. tom pope-11/9/2012
203Very unhappy with the offering (namely the price) but holding for key data in 1Hmcbio111/9/2012
202Deep breath, now that the shares were again pumped into a deeply discounted offescaram(o)uche-11/9/2012
201Thanks for the link, very thoughtful. Rickscaram(o)uche-11/6/2012
200I posted notes on the call here: siliconinvestor.com . Maybe it's just me,mcbio-11/5/2012
199Pharmas (plural!) are discussing a 797 license. Not bad, and I stand corrected wscaram(o)uche-11/5/2012
198Cool. Late breaker 797 ACR abstract accepted, presentation 11/13. "More escaram(o)uche-11/5/2012
197Thanks. Appreciate any education in this area! You know this, but others may bscaram(o)uche-11/4/2012
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News